SWP
AKBA icon

Stratos Wealth Partners’s Akebia Therapeutics AKBA Stock Holding History

Stratos Wealth Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-90
Closed -$1K – 907
2018
Q3 		$1K Buy
+90
New +$805 ﹤0.01% 2797
2018
Q2 		– Sell
-90
Closed -$1K – 1013
2018
Q1 		$1K Sell
90
-650
-88% -$9.09K ﹤0.01% 2954
2017
Q4 		$11K Buy
+740
New +$12.3K ﹤0.01% 2115

Other funds holding AKBA

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Stratos Wealth Partners's AKBA Position: Q4 2018 in Review

Stratos Wealth Partners sold out of Akebia Therapeutics (AKBA) in Q4 2018, closing a stake of 90 shares — an estimated $1K sold.

Stratos Wealth Partners first reported a position in AKBA in Q4 2017 and held it in 3 quarters. The position peaked at $11K in Q4 2017. 166 funds tracked by Wall St. Rank hold AKBA as of Q4 2018.

  • Stratos Wealth Partners reported no remaining Akebia Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Stratos Wealth Partners sold 90 Akebia Therapeutics shares in Q4 2018, an estimated $1K.
  • Stratos Wealth Partners first reported a position in Akebia Therapeutics in Q4 2017 and held it in 3 quarters.
  • Stratos Wealth Partners's Akebia Therapeutics position peaked at $11K in Q4 2017.
  • 166 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2018.

Based on Stratos Wealth Partners's 13F filing for Q4 2018, filed 8 Feb 2019.